NM_004656.4:c.438-2A>G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004656.4(BAP1):c.438-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,140 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_004656.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BAP1 | NM_004656.4 | c.438-2A>G | splice_acceptor_variant, intron_variant | Intron 6 of 16 | ENST00000460680.6 | NP_004647.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152140Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74316
ClinVar
Submissions by phenotype
BAP1-related tumor predisposition syndrome Pathogenic:1
- -
not provided Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.438-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 7 in the BAP1 gene. This alteration has been observed in individuals with a personal and/or family history that is consistent with BAP1-related disease (Testa JR et al. Nat Genet, 2011 Aug;43:1022-5). In vivo mouse studies have shown that mice with this alteration are significantly predisposed to BAP1-associated tumors (Kadariya Y et al. Cancer Res, 2016 05;76:2836-44). RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data; Testa JR et al. Nat Genet, 2011 Aug;43:1022-5). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at